keyword
MENU ▼
Read by QxMD icon Read
search

erythema multiforme

keyword
https://www.readbyqxmd.com/read/28648978/the-thymus-and-activation-regulated-chemokine-tarc-level-in-serum-at-an-early-stage-of-a-drug-eruption-is-a-prognostic-biomarker-of-severity-of-systemic-inflammation
#1
Takayoshi Komatsu-Fujii, Yuko Chinuki, Hiroyuki Niihara, Kenji Hayashida, Masataka Ohta, Ryota Okazaki, Sakae Kaneko, Eishin Morita
BACKGROUND: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation...
June 22, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28644551/erythema-multiforme-like-lesions-in-primary-cutaneous-aggressive-cytotoxic-epidermotropic-cd8-t-cell-lymphoma-a-diagnostic-and-therapeutic-challenge
#2
Carlo Tomasini, Mauro Novelli, Daniele Fanoni, Emilio Francesco Berti
Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (pCAECD8+ CTCL), is an extremely rare, rapidly progressing cutaneous lymphoma, with frequent systemic involvement, first recognized as a distinct clinicopathologic entity by Berti et al in 1999. (1) As the name suggests, this entity has an aggressive behavior and exhibits marked epidermotropism on histopathologic analysis. Conventional treatment modalities for classic CTCL are often ineffective and the prognosis is poor with a median survival of 12 months...
June 23, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28633739/autoimmune-progesterone-dermatitis-presenting-as-fixed-drug-eruption-a-case-report
#3
Raya Mokhtari, Mozhdeh Sepaskhah, Fatemeh Sari Aslani, Ladan Dastgheib
Autoimmune progesterone dermatitis (APD) is a rare disorder characterized by periodic skin lesions that erupt during the luteal phase of the menstrual cycle. Clinical manifestations of APD is caused by an unusual allergy to progesterone and has a wide range of clinical manifestations from eczema and urticaria to angioedema and erythema multiforme. A 46-year-old woman described recurrent, round erythematous plaques on the lower lip, both forearms and buttocks. These skin eruptions waxed and waned for 10 months, reoccurring 3-4 days before menstruation...
June 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28621007/effectiveness-of-a-fixed-combination-formula-of-ombitasvir-paritaprevir-ritonavir-for-hepatitis-c-virus-infection-in-patients-on-maintenance-haemodialysis
#4
Norihiko Morisawa, Yohei Koshima, Satoru Kuriyama, Momoko Matsuyama, Naomi Hayashi, Jun-Ichi Satoh, Morimasa Amemiya, Takashi Yokoo
A fixed-dose formula that combines Ombitasvir (OBV), Paritaprevir (PTV) and Ritonavir (RTV) has been launched into the field of anti-HCV therapy in Japan for patients infected with HCV genotypes 1 and 2 in 2015. However, little is yet known as to the efficacy and safety of this novel therapy in patients on maintenance haemodialysis (HD). The present report describes a preliminary experience in 10 patients (five males and five females) who underwent maintenance HD. All of them had HCV genotype 1b, without having the resistance-associated variants at Y93 or L31 in the nonstructural proteins 5A (NS5A) region...
July 2017: Nephrology
https://www.readbyqxmd.com/read/28569171/oral-mucosal-lesions-in-teenagers-a-cross-sectional-study
#5
Francesca Amadori, Elena Bardellini, Giulio Conti, Alessandra Majorana
BACKGROUND: Adolescence is a period of transition to adulthood. Little is known about oral mucosal lesions (OMLs) in teenagers, in which the emergence of new habits, unfamiliar to children, could affect the type of lesions. The aim of this study was to evaluate the distribution of oral mucosal lesions (OMLs) in a wide sample of adolescents. METHODS: A retrospective cross-sectional study was carried out examining all medical records of adolescents (aged 13-18 years) treated at the Dental Clinic of the University of Brescia (Italy) in the period from 2008 to 2014...
May 31, 2017: Italian Journal of Pediatrics
https://www.readbyqxmd.com/read/28568680/mucositis-secondary-to-chlamydia-pneumoniae-infection-expanding-the-mycoplasma-pneumoniae-induced-rash-and-mucositis-concept
#6
Ander Mayor-Ibarguren, Marta Feito-Rodriguez, Jéssica González-Ramos, Teresa Del Rosal-Rabes, Francisco Javier González-Sainz, Alba Sánchez-Orta, Raul de Lucas-Laguna
The term Mycoplasma pneumoniae-induced rash and mucositis (MIRM) was recently proposed to identify the mucocutaneous condition secondary to M. pneumoniae infection that had historically been regarded among the more confusing pathologies of erythema multiforme and Stevens-Johnson syndrome. Based on a number of previous reports, these syndromes require differentiation since they have different prognoses and specific treatment requirements. We report a case of oral and genital erosions that strongly resembled MIRM without rash but were found to be secondary to a Chlamydia pneumoniae infection...
June 1, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28559809/fuchs-syndrome-medical-treatment-of-1-case-and-literature-review
#7
Rémy Gossart, Eve Malthiery, Fanny Aguilar, Jacques-Henri Torres, Marie-Alix Fauroux
Fuchs syndrome is a particular type of erythema multiforme major; the lesions are only found on the mucosae and specifically affect oral, ocular, and genital mucosae. The cause is not always immediately apparent, which is why this pathology requires a rigorous, detailed clinical examination to eliminate a differential diagnosis. The severity of the symptoms, particularly of oral and ocular symptoms, requires immediate treatment. The treatment of this pathology requires a multiple-drug regime. Through a clinical case study, the objective of this work is to help guide practitioners when diagnosing and treating this pathology as no current consensus exists on these 2 subjects...
January 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28543859/pustular-erythema-multiforme-major-associated-with-atypical-pneumonia
#8
R Wolf, S Ständer, O Well, L Frey, I Klier, S Brunner, M Flaig, A Wollenberg, T Ruzicka
A 52-year-old male patient presented to the hospital with severe difficulties swallowing, sore eyes and an asymptomatic skin rash. The patient was fully oriented, vital signs were normal. Two days before admission to the hospital, the referring physician had suspected an upper respiratory tract infection and had started treatment with oral cefuroxime while also prescribing ibuprofen for sore throat. This article is protected by copyright. All rights reserved.
May 23, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28457003/efficacy-and-safety-of-ombitasvir-paritaprevir-ritonavir-in-dialysis-patients-with-genotype-1b-chronic-hepatitis-c
#9
Masanori Atsukawa, Akihito Tsubota, Yohei Koushima, Tadashi Ikegami, Kouji Watanabe, Noritomo Shimada, Shinichi Sato, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Taeang Arai, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Katsuhiko Iwakiri
AIM: From a pharmacokinetic viewpoint, ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety that have not yet been addressed in patients undergoing dialysis. METHODS: A retrospective, multicenter study evaluated the outcome of 12-week ombitasvir (NS5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir combination therapy for dialysis patients...
April 29, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28398413/imatinib-mesylate-induced-lichenoid-drug-eruption
#10
Erin H Penn, Hye Jin Chung, Matthew Keller
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash...
March 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28396069/lichenoid-and-interface-dermatoses
#11
REVIEW
Alejandro A Gru, Andrea L Salavaggione
The terms 'lichenoid' and 'interface' dermatitis are often used interchangeably to describe an inflammatory pattern characterized histologically by damage to the basal keratinocytes in the epidermis. The mechanism of cell damage of such cells is now best understood as apoptosis, or programmed cell death. This inflammatory pattern of dermatoses, is also accompanied frequently by a band of lymphocytes and histiocytes in the superficial dermis, that often obscures the dermal-epidermal junction, hence the term 'lichenoid'...
May 2017: Seminars in Diagnostic Pathology
https://www.readbyqxmd.com/read/28374407/cutaneous-manifestations-of-diabetes-mellitus-a-review
#12
REVIEW
Ana Luiza Lima, Tanja Illing, Sibylle Schliemann, Peter Elsner
Diabetes mellitus is a widespread endocrine disease with severe impact on health systems worldwide. Increased serum glucose causes damage to a wide range of cell types, including endothelial cells, neurons, and renal cells, but also keratinocytes and fibroblasts. Skin disorders can be found in about one third of all people with diabetes and frequently occur before the diagnosis, thus playing an important role in the initial recognition of underlying disease. Noninfectious as well as infectious diseases have been described as dermatologic manifestations of diabetes mellitus...
April 3, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28352933/erythema-multiforme-following-pneumococcal-vaccination
#13
Alexandra Monastirli, Efstathia Pasmatzi, George Badavanis, Dionysios Tsambaos
Erythema multiforme (EM) is an acute and usually self-limited immune-mediated mucocutaneous disorder that is a hypersensitivity reaction to drugs, infections, and vaccines. Clinically, it is characterized by maculopapular, target-like lesions symmetrically distributed on the extremities (minor form) or additionally affecting one or more mucous membranes and causing epidermal detachment involving < 10% of the total body surface area (major form). We report a novel association between pneumococcal vaccination and the development of EM in a 2...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28338219/human-orf-complicated-by-epidermolysis-bullosa-acquisita
#14
E Zuelgaray, C Salle de Chou, J Gottlieb, M Battistella, M D Vignon-Pennamen, M Bagot, F Guibal, J D Bouaziz
Orf is a DNA parapoxvirus transmitted to humans by contact with infected goats and sheep. Many complications have been reported after Orf infection including erythema multiforme. A few cases of auto-immune bullous dermatosis complicating Orf disease have been reported to date, usually characterized by tense blisters eruptions with or without mucosal involvement, linear deposition of C3, IgG and/or IgA along the basement membrane and negativity of indirect immunofluorescence analysis and ELISA assays (performed in 4 of 11 reported cases) against target antigens of bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullosa acquisita, except one case of mucosal pemphigoid with antilaminin-332 antibodies...
March 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28330775/novel-interferon-%C3%AE-enzyme-linked-immunospot-assay-using-activated-cells-for-identifying-hypersensitivity-inducing-drug-culprits
#15
Kenichi Kato, Asami Kawase, Hiroaki Azukizawa, Takaaki Hanafusa, Yukinobu Nakagawa, Hiroyuki Murota, Shimon Sakaguchi, Hideo Asada, Ichiro Katayama
BACKGROUND: The drug-induced lymphocyte stimulation test (DLST), also referred to as lymphocyte transformation test (LTT), is used to identify the culprit drug in cases of cutaneous adverse drug reactions (cADR). Although DLST is a widely used in vitro test, its sensitivity and specificity are unsatisfactory. Recent reports suggest that the detection of drug-induced interferon (IFN)-γ production using enzyme-linked immunoSpot (ELISpot) assay (conventional IFN-γ ELISpot) is useful for identifying culprit drugs in cADR cases...
June 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28329504/erythema-multiforme-as-a-reaction-to-imiquimod-5-cream
#16
Daniel A Yanes, Jessica A Kaffenberger, David R Carr
We describe a patient with erythema multiformefollowing a local site reaction after the use of topicalimiquimod 5% cream and review the literature forprevious reports of this cutaneous adverse effect.
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329479/apremilast-for-treatment-of-recurrent-erythema-multiforme
#17
Tinley Chen, Jacob Levitt, Lauren Geller
Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies...
January 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28325515/-a-new-case-of-rowell-s-syndrome
#18
C Schissler, S Banea, M-C Tortel, A Mahé
INTRODUCTION: This article introduces a new case of Rowell's syndrome, a controversial entity defined by the association of lupus erythematosus and erythema multiforme. OBSERVATION: A 43-year-old woman was diagnosed with lupus erythematosus induced by esomeprazole. Because her eruption did not improve after withdrawal of the drug, hydroxychloroquine was administered. Two weeks later, the patient described new annular lesions on her chest and arms, both erosive and crusted, and some had a target-like appearance...
March 18, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28322362/immunopathogenic-oral-diseases-an-overview-%C3%A2-focusing-on-pemphigus-vulgaris-and-mucous-membrane-pemphigoid
#19
Liviu Feller, Raoul Ballyram, Razia Ag Khammissa, Mario Altini, Johan Lemmer
Pemphigus vulgaris, mucosal pemphigoid (mucous membrane pemphigoid), lichen planus, discoid lupus erythematosus and erythema multiforme are a group of immune-mediated mucocutaneous disorders characterised clinically by the formation of blisters, erosions or ulcers. The oral mucosa is often affected, and sometimes the disease is limited to the mouth. The target antigens, autoreactive immune responses, microscopic features, treatment and prognosis vary from one disease to the other. Treatment aims to eliminate exogenous risk factors, suppress the pathogenic immuno-inflammatory reactions, promote healing and prevent infection...
2017: Oral Health & Preventive Dentistry
https://www.readbyqxmd.com/read/28295542/unexpected-recalcitrant-course-of-drug-induced-erythema-multiforme-like-eruption-and-interstitial-pneumonia-sequentially-occurring-after-nivolumab-therapy
#20
Hisashi Nomura, Hayato Takahashi, Satsuki Suzuki, Yuichi Kurihara, Shotaro Chubachi, Ichiro Kawada, Hiroyuki Yasuda, Tomoko Betsuyaku, Masayuki Amagai, Takeru Funakoshi
Vemurafenib improves survival of melanoma patients. However, cutaneous side-effects commonly occur in them. Nivolumab and ipilimumab are monoclonal antibodies against programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4, both of which regulate excessive T-cell activation. Although these agents induce antitumor immunity against melanoma, the modified immune condition may result in an unexpected adverse reaction which has not been observed previously. Herein, we report a case who manifested severe erythema multiforme-like eruption with mucosal involvement associated with vemurafenib following nivolumab...
March 11, 2017: Journal of Dermatology
keyword
keyword
3827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"